Small Cap Feast

Small Cap Feast – 11 September 2019

Dish of the Day:

No Joiners Today

Off the Menu:

No Joiners Today

What’s Cooking in the IPO Kitchen?


AMRYT PHARMA PLC— a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or orphan diseases have raised $60m before expenses and will relist on the AIM Market on the 25/09/2019


WORLD HIGH LIFE—The Investment Vehicle is to identify investment opportunities and acquisitions in legal Medicinal Cannabis, Hemp and CBD wellness sectors. Has raised £2,398,309 through three issues of Ordinary Shares to private subscribers. Due 12 Sep.

Rumours and  Speculation

Press reports that Georgina Energy will join the standard list at the end of this month. Georgina is acquiring the EP127 licence in the Northern Territory, Australia, which has significant helium potential. It is raising up to £10m

Breakfast Buffet

SigmaRoc (SRC.L) 40.2p £69.9m

SigmaRoc has conditionally agreed to purchase Belgian sea defence rock quarrying group, Stone Holdings S.A. , at 4.4 times three year average EBITDA, for a transaction value of up to 2.2m, comprising a combination of cash and new ordinary shares in SigmaRoc at a deemed price of 50p per share;

Renowned industrialist and one of Stone’s current owners, Jacques Emsens, to join to the Board of SigmaRoc as a Non-Executive Director, following completion of the acquisition of Stone and subject to customary director due diligence;

Notice of General Meeting to request additional authorities to issue new ordinary shares of 1p each in the Company’s share capital (‘Ordinary Shares’), thereby enabling SigmaRoc to execute certain pipeline transactions in Q4 2019.

Science in Sport (SIS.L) 52.8p £64.9m

 The premium performance nutrition company serving elite athletes, sports enthusiasts and the gym lifestyle community, is pleased to announce the appointment of James Simpson as Chief Financial Officer. James, an experienced finance executive with a track record in the e-commerce and consumer sectors, will join the Group, and Board, on 26 September 2019.

He joins Science in Sport from ASOS plc, the AIM-listed fashion e-tailer, where he held the title of Operational Finance Director. Prior to ASOS, James held senior financial roles at the consumer businesses Britvic plc and Tesco plc.

James qualified as an accountant with PwC in 1998. His early career was in audit at PwC after which he worked in finance roles at Cadbury Schweppes, L’Oreal and Royal Dutch Shell before joining Tesco.”

88 Energy (88E.L) 0.7p £44.3m

Proposed placing of up to A$10m at a price per Placing Share of A$0.0125 (equivalent to £0.007)  ,a discount of 20 per cent. to the volume weighted average price on the Australian Securities Exchange for the thirty days to 10 September 2019. The Bookbuild will open with immediate effect following release of this announcement.

The proceeds of the Placing, together with the Company’s existing cash reserves, will be used to fund the ongoing evaluation of the conventional and unconventional prospectivity of the Company’s existing assets, including any potential costs in respect of the Charlie-1 well which is due to be drilled in Q1 CY2020, and to enable it to identify and exploit new opportunities on the North Slope of Alaska.

Charles Taylor (CTR.L) 225p £175m

HY Jun 19 results. Revenue +15% to £141.7m.

Adjusted EBITDA +81% to £17m. 

Adjusted EPS +20% to 7.67p.

“Charles Taylor performed well in H1 2019.  We are successfully executing our strategy to grow the business.  Our focus on expanding our Claims Services and InsureTech businesses was achieved through new clients wins and solid organic growth with Claims Services delivering an improved margin, and InsureTech delivering a close to break-even operating result. While revenues from Insurance Management were marginally down, we delivered an increase in profits.  Together this resulted in strong growth in the Group’s revenue, adjusted EBITDA and adjusted profit before tax.”

ECO Animal Health (EAH.L) 367p £248m

ECO Animal Health Ltd a wholly owned subsidiary of ECO Animal Health Group plc,  has entered into a second worldwide exclusive research partnership with The Pirbright Institute, United Kingdom, to develop another novel vaccine for use in chickens.

Innovative technologies developed at Pirbright will use a Marek’s disease virus vector to express multiple protective components against the economically important poultry viral diseases of infectious bursal disease virus (IBDV), Newcastle disease virus (NDV) and infectious laryngotracheitis virus (ILTV) which cause significant systemic and respiratory damage.

The global poultry biologicals market is worth c. $2.3 billion and forecast to grow with a CAGR of 5-6%. The Marek’s disease, IBDV, NDV and ILTV segments are collectively worth c. $470m.

Armadale Capital (ACP.L) 1.88p £7.04m

Assay results from its final diamond drilling campaign at the Mahenge Liandu Graphite Project in Tanzania which confirm the high-grade near surface mineralisation.

The geological team is confident that it now has sufficient data points to fully define a JORC compliant Mineral Resource update. Importantly, the Resource update will underpin an initial 10-15 year mine life, in respect of only 25-30% of the mineralised ground tested by drilling and incorporated within the Resource.


High-grade, near surface assayed diamond drill intercepts recorded including:

– 5m @ 19.8% total graphite content (“TGC”) from 1m;

– 14m @ 14.3% TGC from 22m;

– 8m @ 15.3% TGC from 7m; and

– 7m @ 16.2% TGC from 22m

KRM22 (KRM.L) 69p £13.2m

Trading update from the technology and software investment company that focuses on risk management for capital markets.  “Further to the trading update announced on 11 July 2019, the Group’s sales pipeline continues to build with a number of opportunities in advanced stages of negotiation and a pipeline value of approximately £1.5m which could close before the end of the year of which approximately 20% is expected to close over the next 60 days. Demand for our products is strong and the ability to package our market risk suite, surveillance offerings and enterprise risk cockpit provides real competitive advantage as well as cost benefits to our customers. The pipeline has increased over the last two months reflecting new opportunities but also that sales did not close during the summer months. As a consequence, revenue and the associated cash flow is now expected to occur later in the second half of the year.”

RiverFort Global Opp(RGO.L) 0.07p £4.4m

Total income generated of £676,000 in the six months to 30 June 2019

Increase in net asset value since the beginning of the year of almost 6%

De-risked investment portfolio with around 90% now comprising debt instruments and cash

NAV per share is at a 49% premium to the period end share price

The Company is continuing to build on the progress made in 2018 and is generating significant level of investment income

Profit for the six month period of £423,000 and cash generated from operations of £417,000

Net profit margin of 63% and operating cash flow margin of 62% achieved during the period

In excess of £2m of cash available for further investment

Conroy Gold (CGNR.L) 4.7p £1.1m

Further assay results from the gold outcrop discovered by the Company in October 2018 and from prospecting north of the Company’s Clontibret gold deposit.


Channel sample extending over 90cm returned 3.1 g/t gold   

Upstream boulder returns results of 3.9 g/t gold and 23.2 per cent. Antimony

Altyn (ALTN.L) 0.78p £20.2m

The  exploration and development company has received approval  for a loan of US$17m (6.5bln Tenge) from Kazakh Bank JSC.

The loan is repayable in instalments over a term of seven years and bears interest at 6%.

The loan will be used to ramp up production at Sekisovskoye and to achieve the Company’s current development plans.

Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.